Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 11:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 3,714 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: FIX Clear all
Completed Not applicable Interventional

Acupressure for Fatigue and Low Back Pain

NCT02106741
View directory record Official record
Conditions
Fatigue, Chronic Low Back Pain
Interventions
Relaxation acupressure, Stimulating acupressure
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Oct 17, 2026, 11:02 PM EDT
Terminated Phase 1 Interventional

5-aza-2-deoxycytidine With Pegylated Interferon-alfa 2B: A Phase I Study With Molecular Correlates

NCT00886457
View directory record Official record
Conditions
Cancer
Interventions
Decitabine and Pegylated Interferon-Alfa 2B
Drug
Lead sponsor
Nevada Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Oct 17, 2026, 11:02 PM EDT
Withdrawn Not applicable Interventional

Validation of a Novel Thoracic Neoplasm Radiotherapy Image Guidance Technique: A Pilot Study

NCT00585819
View directory record Official record
Conditions
Lung Cancer
Interventions
reproduce breathing cycle utilizing spirometry, Freebreathing in Body fix mold
Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 4, 2012 · Synced Oct 17, 2026, 11:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Auriculotherapy During Medication Abortion

NCT03900728
View directory record Official record
Conditions
Abortion Early
Interventions
Auriculotherapy with needles, Auriculotherapy with beads, Placebo Adhesive disks
Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Oct 17, 2026, 11:02 PM EDT
Withdrawn Phase 4 Interventional

Visceral Artery Aneurysm Embolization by the Penumbra Ruby™ Coil System

NCT02079818
View directory record Official record
Conditions
Visceral Artery Aneurysms, Arteriovenous Malformations
Interventions
Penumbra Ruby Coil System
Device
Lead sponsor
Penumbra Inc.
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 12, 2019 · Synced Oct 17, 2026, 11:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Neuromodulation of Lidocaine and Capsaicin Cream Effects on Pain Experience

NCT03102710
View directory record Official record
Conditions
Pain
Interventions
transcranial direct current stimulation (tDCS), Lidocaine cream, Capsaicin cream, Control cream
Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years to 50 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 17, 2026, 11:02 PM EDT
Terminated Phase 3 Interventional Results available

Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer

NCT01987596
View directory record Official record
Conditions
Childhood Choroid Plexus Tumor, Childhood Medulloblastoma, Childhood Pineoblastoma, Childhood Soft Tissue Sarcoma, Childhood Supratentorial Primitive Neuroectodermal Tumor, Neuroblastoma, Osteosarcoma, Retinoblastoma, Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
filgrastim
Biological
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
1 Year to 25 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Oct 17, 2026, 11:02 PM EDT
Recruiting Phase 1 Interventional

Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents

NCT06963346
View directory record Official record
Conditions
Bladder Cancer
Interventions
Romidepsin, Durvalumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 17, 2026, 11:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Interaction Study To Assess the Effect of Food on the Pharmacokinetics of Esomeprazole 20 mg/Acetylsalicylic Acid 81 mg

NCT01163630
View directory record Official record
Conditions
Effect of Food, Pharmacokinetics
Interventions
esomeprazole/ASA Fixed Dose Combination (FDC)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Oveland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2010 · Synced Oct 17, 2026, 11:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharmacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B

NCT05845645
View directory record Official record
Conditions
Healthy Study Participants
Interventions
UCB0599, Esomeprazole, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 17, 2026, 11:02 PM EDT
Recruiting Phase 3 Interventional

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

NCT07277231
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Sonrotoclax, Zanubrutinib, Acalabrutinib, Venetoclax
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
22
States / cities
Duarte, California • Orange, California • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 17, 2026, 11:02 PM EDT
Recruiting Not applicable Interventional

Intracranial Investigation of Neural Circuity Underlying Human Mood

NCT05871372
View directory record Official record
Conditions
Depression, Epilepsy
Interventions
Brain Stimulation, sEEG Stimulation
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
21 Years to 70 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 17, 2026, 11:02 PM EDT
Completed Not applicable Interventional Results available

Evaluate Safety and Efficacy of the OPTIMIZER® System in Subjects With Moderate-to-Severe Heart Failure: FIX-HF-5C

NCT01381172
View directory record Official record
Conditions
NYHA Class III Heart Failure, NYHA Class IV Heart Failure
Interventions
Optimizer System, No intervention: Optimal medical therapy
Device · Other
Lead sponsor
Impulse Dynamics
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
32
States / cities
Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2021 · Synced Oct 17, 2026, 11:02 PM EDT
Completed Phase 1 Interventional

Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)

NCT00660972
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir, Emtricitabine/tenofovir disoproxil fumarate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
15
States / cities
San Diego, California • Aurora, Colorado • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 17, 2026, 11:02 PM EDT
Completed Not applicable Interventional

A Randomized Trial of Changing Medication Adherence In Hypertensive African-American Patients

NCT00248872
View directory record Official record
Conditions
Hypertension
Interventions
Intervention Group
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 110 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 17, 2026, 11:02 PM EDT
Completed Phase 3 Interventional Results available

Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate

NCT03659929
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Amphetamine Sulfate, Placebo
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
31
States / cities
Encino, California • Garden Grove, California • Newport Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Oct 17, 2026, 11:02 PM EDT
Completed Phase 3 Interventional Results available

Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del

NCT03601637
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
LUM, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Months to 23 Months
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
24
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Palo Alto, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2023 · Synced Oct 17, 2026, 11:02 PM EDT
Not listed Phase 4 Interventional

Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease

NCT02691728
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
LDV/SOF FDC
Drug
Lead sponsor
Peter J. Ruane, M.D., Inc.
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2016 · Synced Oct 17, 2026, 11:02 PM EDT
Active, not recruiting Phase 2 Interventional

Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma

NCT03488667
View directory record Official record
Conditions
Gastro Esophageal Junction Cancer, Stomach Cancer, Adenocarcinoma
Interventions
Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab, Adjuvant Treatment - mFOLFOX & Pembrolizumab
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated May 19, 2023 · Synced Oct 17, 2026, 11:02 PM EDT
Completed Not applicable Interventional

The Effects of Cold Liquids on the Swallowing Mechanism in Preterm Infants

NCT01863264
View directory record Official record
Conditions
Dysphagia
Interventions
Cold Thin Liquid Barium
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
Up to 43 Weeks
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 17, 2026, 11:02 PM EDT
Completed Phase 1 Interventional Results available

A Pharmacokinetics Study of MK-7655A in Pediatric Participants With Gram-negative Infections (MK-7655A-020)

NCT03230916
View directory record Official record
Conditions
Suspected or Documented Gram-negative Bacterial Infection
Interventions
IMI/REL FDC
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Day to 17 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
8
States / cities
Little Rock, Arkansas • Orange, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Oct 17, 2026, 11:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

RCT Comparing Robotically-Assisted vs. Manually-Executed Total Knee Arthroplasties

NCT03482349
View directory record Official record
Conditions
Osteoarthritis
Interventions
Total Knee Robotically-Assisted
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
20 Years to 100 Years
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 17, 2026, 11:02 PM EDT
Terminated Phase 1Phase 2 Interventional

Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers

NCT05099549
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Advanced Solid Tumor, Refractory Tumor, Metastatic Tumor
Interventions
AFM24, SNK01
Drug · Biological
Lead sponsor
NKGen Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Los Angeles, California • Santa Monica, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 1, 2024 · Synced Oct 17, 2026, 11:02 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT02406742
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
CC-122, Ibrutinib, Obinutuzumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 79 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
8
States / cities
La Jolla, California • Boston, Massachusetts • Hackensack, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Oct 17, 2026, 11:02 PM EDT